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KEY POINTS
 A primary cutaneous B-cell lymphoma (CBCL) by definition is one in which the lymphoma involves
no other tissue but skin at the time of diagnosis.
 Primary cutaneous follicle center lymphoma and diffuse large B-cell lymphoma, leg type, are unique
clinicopathologic entities, not to be confused with nodal counterparts with similar names.
 The diagnosis of CBCL requires a 4-mm to 6-mm punch biopsy or incisional or excisional biopsy
that includes the reticular dermis and subcutaneous fat.
 Along with histologic differences, the common CBCLs present on different parts of the body in
different age groups.
 The treatment approach may vary widely between observation, local therapy, or systemic therapy
depending on the histology and extent and area of skin involvement. Histology of the lesion deter-
mines prognosis.INTRODUCTION
The skin is the second most common extranodal
site involved by non-Hodgkin lymphomas (NHLs)
after the gastrointestinal tract. By definition, the
designation of a lymphoma as primary to the skin
implies that there is no extracutaneous disease
discovered at diagnosis. As such, the cutaneous
B-cell lymphomas (CBCLs) make up 25% to
30% of all primary cutaneous lymphomas, with
cutaneous T-cell lymphomas (CTCLs) being the
more common subtype.1
Although the clinical presentation of CBCLs
compared with CTCLs is more uniform, clinico-
pathologic correlation is still important and, in the
absence of features clearly suggesting a benign
diagnosis, the evaluation of nonepidermotrophic
or dermal lymphoid cutaneous infiltrate such asThe author has done consulting for Celgene, Pharmacyc
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and physical examination.
The 3 most common histologic types of primary
cutaneous lymphomas as designated in the World
Health Organization (WHO) 2008 Classification of
Tumors of Haematopoietic and Lymphoid Tissues
are primary cutaneous follicle center lymphoma
(PCFCL), extranodal marginal zone lymphoma
(MZL) of mucosa-associated lymphoid tissue
(MALT; previously called primary cutaneous MZL
[PCMZL]), and primary cutaneous diffuse large
B-cell lymphoma (PCDLBCL), leg type. The first
and last of these are recognized as unique entities
in the WHO 2008 classification.2 Although they
carry names and have some histologic similarities
with nodal counterparts, there remain differences
not only in presentation and histology but also inlics.
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Pinter-Brown836natural history, treatment, and outlook. PCMZL,
however, is discussed within the general category
of extranodal MZLs, which are frequently found in
extranodal sites such as skin or stomach. Although
both PCFCL and PCMZL are considered slow-
growing or indolent diseases with an excellent
outlook, PCDLBCL, leg type, is a more aggressive
entity with behavior more similar to its nodal
counterpart.DIAGNOSIS AND STAGING
The diagnosis of a CBCL first requires a biopsy of
these mostly papular or tumoral erythematous to
violaceous skin lesions. To this end, a 4-mm to
6-mm punch biopsy or excisional or incisional bi-
opsy that includes the reticular dermis and fat
should be obtained.
After the diagnosis is confirmed, staging pro-
cedures in addition to history and physical ex-
amination should be performed to evaluate for
extracutaneous disease and anticipate treatment.
Groups such as the National Comprehensive Can-
cer Network (NCCN)3 have suggested performance
of complete blood count (CBC) with differential, a
comprehensive chemistry panel, and lactate dehy-
drogenase level. If a lymphocytosis or immature
cells are seen in the CBC, peripheral blood flow cy-
tometry should be ordered to evaluate for a mono-
typic lymphoid population, which may signify
blood involvement by the lymphoma. In the case
of PCMZL, both a serum protein electrophoresis
and quantitative immunoglobulins should be sent
to evaluate for a paraprotein given the increased
incidence of this finding in this specific entity. Sero-
logic testing for hepatitis B and C, especially if sys-
temic therapies such as rituximab, systemic
steroids, or other immunomodulatory agents are
being considered, and testing for Borrelia burgdor-
feri serologies should be considered. Although an
association between B burgdorferi infection and
CBCL has been made in several European coun-
tries, such a relationship has not been shown in
North American patients and the strength of this as-
sociationmay relate in part to geographic diversity.4
In addition to laboratory testing, PET/computed
tomography (CT) scanning or CT scanning with
contrast of the chest, abdomen, and pelvis should
be performed at diagnosis, but not routinely in
follow-up unless clinical or laboratory parameters
are concerning for extracutaneous progression.
Bone marrow examination should be performed
if the diagnosis is PCDLBCL, leg type, and consid-
ered if the diagnosis is PCFCL.
Although a TNM (tumor, node, metastasis) clas-
sification for cutaneous lymphomas other than
MF/SS has been proposed,5 unlike the largergroup of NHLs, the histology of these diseases
remains the main determinant of a patient’s
outcome. However, the TNM classification can
be used effectively for the documentation of ana-
tomic location and extent of disease involvement.6
The histology of primary cutaneous lymphomas
is discussed in depth elsewhere in this issue, the
clinical presentation and treatment of the 3 most
common forms of CBCLs are discussed here se-
parately. Other uncommon CBCLs, such as in-
travascular large B-cell lymphoma, a subtype of
diffuse large B-cell lymphoma (DLBCL) that may
present primarily in skin, and cutaneous
immunodeficiency-associated lymphoproliferative
diseases such as Epstein-Barr virus (EBV)–positive
mucocutaneous ulcer are briefly discussed.PRIMARY CUTANEOUS FOLLICLE CENTER
LYMPHOMA
The most common type of primary CBCL, PCFCL,
represents 60% of all cases. The median age of
patients is 51 years, with a slight male predomi-
nance (1.5:1).7,8 Lesions are firm, erythematous
to violaceous nodules or plaques with a smooth
skin surface; ulcerations are rarely observed.
These lesions characteristically present as solitary
or localized skin lesions on the scalp, head and
neck, or trunk. Only 5% present on the leg and
15% are multifocal.7,8
In contrast with its nodal counterpart, follicular
lymphoma, PCFCL does not necessarily have
CD10 staining by immunohistochemistry, and
may have negative or faint staining with bcl-2.
When present, these positive stains raise suspicion
for secondary rather thanprimary skin involvement.
Surface immunoglobulin (Ig) G is usually negative in
PCFCL, in contrast with follicular lymphoma. In
addition, PCFCL is not graded as nodal follicular
lymphoma in termsof number or proportion of large
cells noted.2
Although the rate of cutaneous relapse with
PCFCL reaches30%, theconditionhasanexcellent
prognosis, with a 5-year survival of greater than
95%. Although some patients experience sponta-
neous regression, approximately 10% experience
extracutaneous dissemination.7,8EXTRANODAL MARGINAL ZONE LYMPHOMA
OF MUCOSA-ASSOCIATED LYMPHOID TISSUE
Primary cutaneous MALT lymphomas are
described in the WHO classification of 2008 as
part of the general group of extranodal MZLs of
MALT in which there is often a role described for
a chronic antigenic stimulus to lymphomagenesis.
Approximately 11% of MALT lymphomas involve
Management of CBCL 837the skin,9 with gastrointestinal tract involvement
being the most common extranodal site; MALT
lymphomas of the skin represent approximately
7% of all skin lymphomas, either of B-cell or
T-cell origin. Patients with PCMZL have a slightly
higher median age of 55 years than PCFCL with
a male predominance (2:1).7,8 Lesions present as
erythematous papules, nodules, or plaques, espe-
cially on the extremities and trunk.
MALT lymphomas as a group are distinguished
from other B-cell lymphomas by having no specific
associated marker. They may express IgM and
show light chain restriction, distinguishing them
from reactive lymphoid infiltrates. AlthoughPCMZL
is classified with other MALT lymphomas, it has
distinctive features, including the finding of plas-
macytic differentiation within the lymphocytic infil-
trate, which is an especially common finding in
the skin lesions. Overall, 30% of patients show a
serum monoclonal protein.10 The higher incidence
of monoclonal proteins in PCMZL compared with
other NHLs reflects the finding of concurrent plas-
macytic differentiation or plasmacytosis. The
finding of a monoclonal protein provides clinicians
with another parameter with which to follow the pa-
tient’s clinical course.
The 5-year survival is 100%, although recur-
rences are common and occur in up to half of pa-
tients.11,12 Waxing and waning lesions, and
occasional spontaneous remission, can be seen.PRIMARY CUTANEOUS DIFFUSE LARGE
B-CELL LYMPHOMA, LEG TYPE
In contrast with the previous CBCLs, PCDLBCL,
leg type, is considered an aggressive lymphoma
with a poor outcome. It represents 4% of all cuta-
neous lymphomas and 20% of all primary CBCLs,1
and affects the elderly with a median age of
70 years. The predominant gender is female, with
a 1:3 to 1:4 ratio.13 The condition presents as red
or violaceous tumors commonly arising on 1 or
both legs, with 10% to 15% of cases involving
other sites.7,8,14 The lymphoma frequently dissem-
inates to extracutaneous sites.
On histology, large transformed B-lymphocytes
with frequent mitotic figures are seen. The cells
show monotypic IgG, and have strong expression
of bcl-2, IRF4/MUM-1, and bcl-6. Ten percent of
cases lack bcl-2 or MUM-1. CD10 is usually nega-
tive. In this way, both immunohistochemistry and
gene expression profiling have many similarities
to nodal diffuse large B-cell lymphoma of the acti-
vated B-cell (ABC) phenotype, which has been
shown to have a worse prognosis than other phe-
notypes of DLBCL, like the germinal center pheno-
type given therapies such as RCHOP. Fluorescentin situ hybridization may show both c-myc, bcl-6,
and bcl-2 mutations, similar to the so-called tri-
ple-hit diffuse large B-cell lymphoma, which has
a poor prognosis.15
In this elderly population of patients, presenta-
tion with multiple skin lesions at diagnosis seems
to be an additional adverse risk factor. Overall,
the 5-year survival is approximately 50%, which
is far worse than the other CBCLs previously
described.13,16OTHER B-CELL LYMPHOMAS THAT PRESENT
IN SKIN
Other lymphomas that have been described as
presenting primarily in skin include intravascular
large B-cell lymphoma, a rare form of extranodal
lymphoma characterized by intravascular growth
of large B cells, especially in small vessels and
capillaries in brain and skin, a presentation that
has been described in Western countries. This
lymphoma primarily affects an older population
with a median age of 67 years.17 Skin lesions
may look like livedo (with a reticular erythema),
may resemble panniculitis, or may present as
painful telangiectasia or nodules. Conventional
staging often does not show extracutaneous dis-
ease because the lymphoma spares lymph nodes,
although it may present in any other tissue. Some
investigators have described a more indolent
behavior of this usually fatal lymphoma in which
only the skin is affected.18
T cell–richB-cell lymphoma, a type of largeB-cell
lymphoma rich in T-cells in association with a
limited number of scattered large malignant B
cells19 and plasmablastic lymphomas, have also
beendescribedaspresentingprimarily in skin; plas-
mablastic lymphomas often being seen in individ-
uals infectedwithhuman immunodeficiencyvirus.20
Mucocutaneous ulcer represents an EBV-driven
cutaneous lymphoproliferative disorder that is
associated with immunodeficiency. It presents
with sharply demarcated ulcers in skin or mucosa,
largely in individuals with either immune senes-
cence of age or iatrogenic immune suppression.
These ulcers show spontaneous regression about
45% of the time.21TREATMENT OF THE INDOLENT CUTANEOUS
B-CELL LYMPHOMAS: PRIMARY CUTANEOUS
FOLLICLE CENTER LYMPHOMA AND
MUCOSA-ASSOCIATED LYMPHOID TISSUE
LYMPHOMA
In general, treatment of these entities may vary de-
pending on the presentation of disease, with pa-
tients presenting with a solitary lesion or lesions
Pinter-Brown838limited to a single anatomic site being approached
differently from patients presenting with general-
ized or treatment-refractory disease or evidence
of extracutaneous spread. Data supporting these
forms of treatment are limited to small retrospec-
tive or case studies, and groups such as NCCN,3
the European Organisation for Research and
Treatment of Cancer, and the International Society
for Cutaneous Lymphomas22 have provided
consensus opinions of a group of experts because
of this lack of data in the literature.
Patients presenting with solitary lesions or le-
sions limited to a single anatomic site may be
treated with localized electron beam radiotherapy
or surgical excision. Typical radiation doses are at
least 30 Gy, with a margin of 1 to 1.5 cm around
the lesion. Selected cases may also be closely
observed or treated with topical or intralesional
steroids. These approaches may be particularly
attractive when the site of involvement renders a
surgical or radiotherapeutic approach less desir-
able because of poor cosmetic outcomes, as in
hair-bearing areas of the body, large lesions, or
involvement of the face. The use of cryotherapy
has also been described.23
Patients with more generalized or refractory le-
sions may also be treated with similar approaches
or with systemic treatments such as rituximab, a
chimeric anti-CD20 antibody, with or without
maintenance infusions, or radioimmunotherapy
with an anti-CD20 antibody conjugate. Clinicians
should be aware that case reports of localized
edema or urticaria have been described in the
CBCL skin lesions in these patients after systemic
treatment with rituximab.24,25
Patients with the development of extracutane-
ous disease should be treated as patients with
nodal follicular lymphoma.TREATMENT OF PRIMARY CUTANEOUS
DIFFUSE LARGE B-CELL LYMPHOMA, LEG
TYPE
The treatment of patients presenting with a single
lesion has been described with local radiation, a
choice that may be especially attractive in this
elderly patient population, or with the addition of
systemic multiagent chemotherapy such as rituxi-
mab with CHOP (cyclophosphamide, adriamycin,
vincristine, and prednisone). Patients with general-
ized lesions are likely to be treated as in nodal
DLBCLs. As in the more indolent CBCLs, there
are no randomized controlled data to guide treat-
ment choices in this entity and treatment may pro-
ceed in keeping with individual and institutional
experience. In the future, reports are anticipated
of less toxic treatment alternatives that havebeen or are being explored in nodal DLBCL, ABC
phenotype, such as the use of nuclear factor
kappa B inhibitors such as bortezomib,26 immuno-
modulatory drugs such as lenalidomide with ritux-
imab27 (so-called R2), or newer drugs such as
ibrutinib,28 an oral Bruton tyrosine kinase pathway
inhibitor that seems to have preferential activity in
DLBCL of the ABC phenotype.SUMMARY
The diagnosis of primary CBCL requires that the
evaluation for a more widespread lymphoma has
been negative. In contrast with the more common
CTCLs, these lymphomas have a more consistent
clinical presentation and, on histologic examina-
tion of representative skin biopsies, are not epi-
dermotrophic, instead involving the dermis and
subcutaneous tissue. Treatment may range from
observation, to topical therapies, to systemic
therapies, depending on the histology, degree
and area of skin involvement, patient perfor-
mance, and comorbidities, and may be influenced
by individual practitioner and institutional experi-
ence and capabilities. Randomized, controlled
data are lacking in the medical literature to direct
optimal treatment of all CBCLs. The indolent
types of CBCL, PCFCL and PCMZL of MALT lym-
phoma, have an excellent prognosis regardless of
treatment selected. In the more aggressive and
dire PCDLBCL, leg type, which affects older and
perhaps more debilitated patients, published
experience is anticipated with novel, more tar-
geted agents and perhaps less toxic agents that
show activity in the similar lymphoma, nodal
DLBCL of ABC type.REFERENCES
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